{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gaillard B"],"funding":["Conseil Régional d’Alsace"],"pagination":["581260"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7566913"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8"],"pubmed_abstract":["Alkylphospholipids (APLs) have elicited great interest as antitumor agents due to their unique mode of action on cell membranes. However, their clinical applications have been limited so far by high hemolytic activity. Recently, cationic prodrugs of erufosine, a most promising APL, have been shown to mediate efficient intracellular gene delivery, while preserving the antiproliferative properties of the parent APL. Here, cationic prodrugs of the two APLs that are currently used in the clinic, miltefosine, and perifosine, are investigated and compared to the erufosine prodrugs. Their synthesis, stability, gene delivery and self-assembly properties, and hemolytic activity are discussed in detail. Finally, the potential of the pro-miltefosine and pro-perifosine compounds <b>M</b> <sub><b>E12</"],"journal":["Frontiers in chemistry"],"pubmed_title":["Dual Gene Delivery Reagents From Antiproliferative Alkylphospholipids for Combined Antitumor Therapy."],"pmcid":["PMC7566913"],"funding_grant_id":["2015"],"pubmed_authors":["Remy JS","Gaillard B","Pons F","Lebeau L"],"additional_accession":[]},"is_claimable":false,"name":"Dual Gene Delivery Reagents From Antiproliferative Alkylphospholipids for Combined Antitumor Therapy.","description":"Alkylphospholipids (APLs) have elicited great interest as antitumor agents due to their unique mode of action on cell membranes. However, their clinical applications have been limited so far by high hemolytic activity. Recently, cationic prodrugs of erufosine, a most promising APL, have been shown to mediate efficient intracellular gene delivery, while preserving the antiproliferative properties of the parent APL. Here, cationic prodrugs of the two APLs that are currently used in the clinic, miltefosine, and perifosine, are investigated and compared to the erufosine prodrugs. Their synthesis, stability, gene delivery and self-assembly properties, and hemolytic activity are discussed in detail. Finally, the potential of the pro-miltefosine and pro-perifosine compounds <b>M</b> <sub><b>E12</","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020","modification":"2025-04-18T18:50:36.366Z","creation":"2020-11-03T08:03:42Z"},"accession":"S-EPMC7566913","cross_references":{"pubmed":["33134279"],"doi":["10.3389/fchem.2020.581260"]}}